Sugi Predict

Sugi Predict / Compounds / SCHEMBL514966

SCHEMBL514966

SCHEMBL514966

CN[C@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)NC(CCCNC(=N)N)C(=O)c1nc2ccccc2s1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F2 P00734 8/20 0.59
▸ PRSS1 P07477 4/20 0.47
▸ PRKD3 O94806 2/20 0.47
▸ F10 P00742 2/20 0.47
▸ PLAU P00749 2/20 0.47
▸ PLAT P00750 2/20 0.47
▸ PRKCG P05129 2/20 0.47
▸ PRKCB P05771 2/20 0.47
▸ F7 P08709 2/20 0.47
▸ PRKCA P17252 2/20 0.47
▸ PRKCH P24723 2/20 0.47
▸ PRKCI P41743 2/20 0.47
▸ PRKCE Q02156 2/20 0.47
▸ PRKCQ Q04759 2/20 0.47
▸ PRKCZ Q05513 2/20 0.47
▸ PRKCD Q05655 2/20 0.47
▸ PRKD1 Q15139 2/20 0.47
▸ TPSAB1 Q15661 1/20 0.47
▸ PRSS2 P07478 1/20 0.46
▸ PRSS3 P35030 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8939669 0.92 F2 (0.54) F2PRSS1PRKD3F10PLAU
SCHEMBL24115250 0.89 F2 (0.59) F2PRSS1TPSAB1
SCHEMBL24131389 0.89 F2 (0.59) F2PRSS1TPSAB1
SCHEMBL24131608 0.89 F2 (0.59) F2PRSS1TPSAB1
SCHEMBL24131464 0.89 F2 (0.59) F2PRSS1TPSAB1
SCHEMBL5860097 0.89 F2 (0.58) F2PRSS1TPSAB1
SCHEMBL5860154 0.88 F2 (0.60) F2PRSS1TPSAB1
SCHEMBL514967 0.88 F2 (0.60) F2PRSS1PRKD3F10PLAU
SCHEMBL30171117 0.88 F2 (0.76) F2PRSS1PRKD3F10PLAU
SCHEMBL24131280 0.88 F2 (0.54) F2PRSS1TPSAB1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120027706-A1 METHODS FOR TREATING SKIN PIGMENTATION SHAPIRO STANLEY S (US) 2012-02-02 — — US disclosed
US-8039026-B1 Methods for treating skin pigmentation JOHNSON & JOHNSON CONSUMER COMPANIES, INC (US) 2011-10-18 — — US disclosed
US-20080249029-A1 Administering (S)-N-Methyl-D-phenylalanyl-N-[4-[(aminoiminomethyl)aminol-1-(2-benzothiazolylcarbonyl)butyl-L-prolinamide as a protease activated receptor-2 modulator SHAPIRO STANLEY S 2008-10-09 — — US disclosed
EP-1037653-B1 COMPOSITIONS AND METHODS FOR REGULATING PHAGOCYTOSIS AND ICAM-1 EXPRESSION JOHNSON & JOHNSON CONSUMER (US) 2006-09-06 — — EP disclosed
EP-0948308-B1 METHODS FOR TREATING SKIN PIGMENTATION JOHNSON & JOHNSON CONSUMER (US) 2004-02-25 — — EP disclosed
US-20020197244-A1 Compositions and methods for regulating phagocytosis and ICAM-1 expression SEIBERG MIRI (US) 2002-12-26 — — US disclosed
US-6323219-B1 PRODRUGS AND PEPTIDES FOR ANTIINFLAMMATORY AGENTS ORTHO-MCNEIL PHARMACEUTICAL, INC. 2001-11-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120027706-A1 METHODS FOR TREATING SKIN PIGMENTATION TYR, MC1R, NQO1 F2 1151/4885PRSS1 473/4885PRKD3 334/4885
US-20080249029-A1 Administering (S)-N-Methyl-D-phenylalanyl-N-[4-[(aminoiminomethyl)aminol-1-(2-benzothiazolylcarbonyl)butyl-L-prolinamide as a protease activated receptor-2 modulator MC1R, F2RL1, F2R F2 914/4885PRSS1 22/4885PRKD3 1630/4885
US-20020197244-A1 Compositions and methods for regulating phagocytosis and ICAM-1 expression ICAM1, CD47, VCAM1 F2 2338/4885PRSS1 2947/4885PRKD3 2914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.